Last reviewed · How we verify
Control-no treatment
Control-no treatment is a Small molecule drug developed by Pfizer. It is currently in Phase 3 development.
This is a control arm with no active treatment, used as a comparator in clinical trials.
Control-no treatment refers to a comparison group in clinical trials that does not receive any intervention. Verified conditions studied in control-no treatment groups include Locally Advanced Rectal Cancer, Irritable Bowel Syndrome, Chronic Pain, Musculoskeletal Pain, and Musculoskeletal Pain Disorder.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Control-no treatment |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
In phase 3 trials, a no-treatment control arm serves as a baseline to measure the efficacy and safety of an investigational drug against the natural disease course or standard of care. Patients in this arm receive no active pharmaceutical intervention, allowing researchers to quantify the true benefit attributable to the test drug.
Approved indications
Common side effects
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- WEB-BASED FILIAL THERAPY IN PEDIATRIC CANCER (NA)
- Shared Decision-Making Decision Aid for Newly Diagnosed Breast Cancer : A Multi-Center Randomized Controlled Trial (NA)
- Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair (NA)
- Conservative Treatment of Trigger Finger (NA)
- Bedside Bike Early Mobilization Program for Inpatients (NA)
- Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy (NA)
- Cognitive Task Development and Implementation for Functional MRI Studies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control-no treatment CI brief — competitive landscape report
- Control-no treatment updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Control-no treatment
What is Control-no treatment?
How does Control-no treatment work?
Who makes Control-no treatment?
What development phase is Control-no treatment in?
Related
- Manufacturer: Pfizer — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing